RxDoctor Payments Data

Jeremy Payne, APRN

Family · Owensboro, KYNPI 1366058422

Payments from drug & device makers

$5,475in general payments, 2019–2025

Across 334 payments — averaging $16.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$773
  • Johnson & Johnson$688
  • Novartis$512
  • Actelion Pharmaceuticals US, Inc.$479
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$427
  • E.r. Squibb & Sons, L.L.C.$423
  • plus $2K from 20 others

What the payments were for

  • Food & beverage$5,32097%
  • Education$1553%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,475 in reported general payments places this provider in the 90th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$132,866
Medicare patients
1,026
Services billed
1,828

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban177$199,060
EntrestoSacubitril/Valsartan96$107,483
XareltoRivaroxaban63$63,095
JardianceEmpagliflozin73$58,882
FarxigaDapagliflozin Propanediol42$30,332
BrilintaTicagrelor34$22,845
MultaqDronedarone Hcl17$15,508
VerquvoVericiguat14$11,314
Repatha SureclickEvolocumab12$8,716
Metoprolol Succinate327$3,196
Amiodarone Hcl45$2,869
Valsartan73$1,864
Nifedipine ErNifedipine71$1,756
Diltiazem 24hr Er (La)Diltiazem Hcl13$1,278
Amlodipine Besylate246$1,253

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$148$199,060177 claims
NovartisEntresto$512$107,48396 claims
Johnson & JohnsonXarelto$688$63,09563 claims
Boehringer IngelheimJardiance$383$58,88273 claims
AstraZenecaFarxiga, Brilinta$346$53,17676 claims
Sanofi-aventis U.S. LLCMultaq$266$15,50817 claims
MerckVerquvo$298$11,31414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,374 family providers in Kentucky.

Other family in Owensboro

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →